Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
Hiroki YukamiAkihito KawazoeYi-Tzu LinSyohei KoyamaShota FukuokaHiroki HaraNaoki TakahashiTakashi KojimaMasako AsayamaTakako YoshiiHideaki BandoDaisuke KotaniYoshiaki NakamuraYasutoshi KubokiSaori MishimaMasashi WakabayashiTakeshi KuwataMasahiro GotoKazuhide HiguchiTakayuki YoshinoToshihiko DoiHiroyoshi NishikawaKohei ShitaraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Anti-PD-1 antibodies plus regorafenib or lenvatinib for AGC showed promising antitumor activity with a longer follow-up, irrespective of liver metastases status, despite a more immune-suppressive tumor microenvironment in liver metastases.